
Pfizer and 3SBio Finalize Licensing Deal
Pfizer Inc. has announced the completion of a global (excluding China) licensing agreement with Chinese biopharmaceutical company 3SBio Inc., securing exclusive rights to develop, manufacture, and commercialize 3SBio’s experimental cancer therapy, SSGJ-707 …